rubi even rarer diamond
initi buy pt
initi buy base rare platform technolog could broadli
address number blockbust market technolog offer key proof
concept data key catalyst across rare diseas oncolog
immunolog offer investor signific upsid potenti
next year combin strong management offer attract asymmetr
risk/reward time jefferi act joint-bookrunn ipo rubiu
pictur rubiu pioneer new class medicin call red cell
util red blood cell off-the-shelf platform deliv protein interest
via gene therapi insid cell potenti better efficaci safeti dose frequenc
includ known protein insid red blood cell treat orphan diseas due
miss protein pku leader key ligand
surfac cell activ immun system treat cancer immunotherapi
antigen present treat autoimmun diseas induc toler platform
potenti address market compani alreadi
gener hundr larg early-stag pipelin rct drug
address market shore leadership posit build
key manufactur capabl critic patent portfolio
think first phase i/iia data key catalyst start de-risk
pku market also could unlock import much bigger platform
valu quickli start phase i/iia pku pt data potenti
replac miss protein pal insid red blood cell therapi
fairli de-risk alreadi pegyl version fda approv palynziq
reduc diseas biomark phe show signific reduct phe
would show first sign platform safe efficaci would de-risk add
valu program cancer express could show
high respons rate phase i/ii follow year
long-term uniqu potenti big idea biotech
platform differenti applic across mani diseas prove
work platform comp trade early-stag cll
higher phase de-risk stage etc
attract play uniqu differenti platform big upsid potenti
next year earli data play
gener estim cash debt
quarterli ep estim jefco estim
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
base case base dcf analysi
pku nsclc
probabl adjust revenu indic
also account portion cash well ascrib
platform valu compani valuat
like appreci trade
compani initi clinic develop rtx-
follow-on program releas initi data
start could de-risk platform
found flagship pioneer base
mit rubiu built
discoveri
could
orphan cancer autoimmun diseas
upsid scenario consid higher
probabl pku nsclc
think upsid target could easili justifi
show posit data de-
believ addit upsid could driven
posit data studi autoimmun diseas
posit data addit orphan diseas and/or
downsid scenario primarili
consid platform valu cash base
potenti safeti issu aris inabl rtx-
meet primari endpoint key
scenario rubiu product candid could
gener unfavor side effect properti delay
prevent approv limit commerci opportun
result unfavor outcom clinic hold
file ind pku
initi phase i/iia studi pku
interim data phase i/iia studi
initi phase i/ii studi solid
file ind addit orphan oncolog
interim data phase i/ii studi solid
page
pleas see import disclosur inform page report
question debat
stem cell red blood cell
phenylketonuria pku opportun
orphan drug indic treatment chronic refractori gout
orphan drug indic rtx-cb treatment homocystinuria
solid opportun
function artifici antigen present cell aapc
histor project incom statement
histor project balanc sheet
histor project
page
pleas see import disclosur inform page report
initi buy base uniqu proprietari platform combin
cell therapi gene therapi technolog broadli address number key blockbust
diseas market time although pipelin fairli early-stag first ind
technolog play could valuabl platform invest
signific upsid potenti current trade price long-term uniqu
potenti big idea biotech platform differenti
applic across mani diseas prove work platform comp trade
early-stag compani cll higher
phase de-risk platform etc henc current market cap
attract play uniqu differenti platform big
upsid potenti next one two year earli data play
stock catalyst perspect technolog pipelin offer import proof
concept start first key safeti efficaci data pku patient data
read across rare diseas oncolog immunolog offer investor
signific upsid potenti next one two year area start
get de-risk clinic data combin strong manag think offer
attract asymmetr risk/reward opportun time
specif first phase i/ii data key catalyst start de-risk
start phase pku pt data potenti rtx-
incorpor miss protein pal insid red blood cell therapi
fairli de-risk alreadi pegyl version fda approv peg-pal
via reduct substrat biomark phe
show signific reduct phe compar
peg-pal would show first sign platform safe efficaci
would de-risk add valu program cancer
could show high respons rate phase i/ii follow year
base cambridg rubiu pioneer innov class cellular medicin
call red cell util red blood cell off-the-shelf platform
deliv protein interest potenti better efficaci safeti via gene therapi
insid cell therapi overal believ platform potenti
address tam least market compani alreadi
gener hundr larg early-stag pipelin rct drug address
market shore leadership posit build key
manufactur capabl commit invest new squar foot
cell therapi manufactur facil smithfield ri critic patent portfolio
diseas known protein insid red blood cell treat orphan
diseas miss protein pku leader
express import protein pal insid red blood cell deliv
therapi everi month deliveri insid cell shield
pal immun respons cellular shield thu yield greater efficaci
much less frequent administr biomarin palynziq daili
inject black box warn risk seriou anaphylaxi reaction
page
pleas see import disclosur inform page report
oncolog rubiu design express key co-stimulatori ligand
surfac red blood cell drive potent cell-cel
interact activ immun system treat cancer immunotherapi
power stimul adapt immun system activ t-
cell fight cancer attempt
antibodi despit strong pre-clin data earli phase i/ii data
show antibodi accumul liver eventu caus
dose limit liver tox never abl dose high enough get high
respons rate express surfac cell
yield higher efficaci due natur conform surfac rather
antibodi cross-link accumul liver henc improv
safeti therapeut window
autoimmun diseas typic therapi diseas
limit part due chronic lifelong administr pt eventu
progress respond therapi design product candid
express specif autoimmun disease-caus antigen surfac cell
therapi could induc toler antigen prevent foreign
antigen trigger danger immun respons number identifi
autoimmun diseas driven primarili one key antigen
express cell surfac could drive toler induct
also design could sequest remov neutral diseas target
circul tnf-alpha treat autoimmun diseas
also led well-known manag execut number biotech
pharma compani previous execut chairman david epstein novarti
decad includ ceo novarti pharma head novarti oncolog
molecular diagnost unit ceo pablo cagnoni presid onyx pharmaceut
sold previous global head clinic
develop novarti oncolog lastli presid torben straight nissen head
world-wide strateg portfolio manag overse compani
overal think well posit well-fund execut pipelin
next year demonstr earli posit proof concept across
multipl therapeut area describ signific upsid potenti
platform technolog leverag across mani therapeut program
page
pleas see import disclosur inform page report
base case base dcf analysi phenylketonuria
pku non-smal cell lung cancer nsclc probabl adjust
revenu stream indic also ascrib valu rubiu platform
cash valuat
upsid scenario consid higher probabl success rtx-
assign greater valu rubiu platform think rubiu
show work pku solid tumor
believ significantli de-risk program moreov think posit data
program de-risk rubiu orphan diseas oncolog indic addit
upsid potenti come potenti success one autoimmun diseas
current ascrib valu
downsid scenario base potenti safeti issu aris
inabl rubiu meet primari endpoint key
studi scenario could gener unfavor side effect
properti delay prevent approv limit commerci opportun result
unfavor outcom clinic hold letter limit patient uptak minim
sale traction ascrib lower probabl rubiu platform
ascrib valu rubiu cash
page
pleas see import disclosur inform page report
question debat
simplist term rubiu drug get made
work
rubiu collect bone marrow stem cell healthi volunt use gene therapi
rubiu introduc dna stem cell cell express therapeut protein
interest cell cultur turn red blood cell express
therapeut protein red blood cell infus patient treat
diseas insid bodi engin cell perform variou task
depend biotherapeut protein express case orphan diseas
drug replac miss enzym cancer drug activ immun
system autoimmun diseas drug induc immun toler
rubiu rct like safe
red blood cell blood product use two centuri therapi
wide array diseas alon everi year million unit blood
compon use treat variou condit includ trauma cancer
view believ rct like safe given histori widespread use
rbc medicin
potenti risk variou set
novel therapi key pitfal safeti orphan diseas
set think potenti risk prematur releas biotherapeut
protein key risk factor protein use non-human could
elicit potent immun respons anaphylaxi oncolog set
addit safeti think efficaci key risk factor target set
well character autoimmun set efficaci safeti
potenti risk aim therapi induc immun toler diseas
set word dampen alreadi activ immun system express
antigen infus back patient set could
competitor anyth similar
sever biotech compani develop -base therapeut
erytech pharma erydel spa sqz
compani mainli focus load matur red blood cell therapeut
agent erytech success complet phase trial aml
sever drawback erytech approach load matur rbc
via hypoton method requir collect cell prior treatment cell
off-the-shelf therapeut agent amen hypoton load
use hypoton load damag red blood cell reduc durabl
half-lif
didnt anyon els come
rubiu figur uniqu
rubiu platform result confluenc multipl advanc includ
academ research map complex process stem cell enucl red
blood cell differenti high effici forward think flagship
pioneer innov team recogn biotherapeut could
engin modifi stem cell prior differenti use gene therapi
page
pleas see import disclosur inform page report
increas market accept cellular therapi owe fda approv
yescarta kymriah
rct potenti use wide array therapeut area
red blood cell use sourc therapi hundr year thu
use safeti larg character
rubiu initi program diseas larg de-risk pku
establish proof concept pku done rel quickli month
regulatori agenc alreadi demonstr accept rubiu rct
allow compani skip phase studi first product candid rtx-
pku
rubiu hold signific patent estat know-how around use red blood
cell therapeut purpos hard follow-on compani replic
off-the-shelf result readi patient use need
rubiu platform multipl shot goal come blockbust
management team industri veteran experi develop cellular therapi
rubiu abl leverag current red blood cell infus technolog
center administr drug
rubiu abl use product process variou rct product
candid need chang lentivir vector use
red blood cell enucl nucleu divid risk
cancer low
gener therapeut dose univers donor
rubiu develop end end manufactur capabl rct
everyth preclin test human efficaci safeti
unforeseen safeti problem derail diseas program therapeut area
unexpect safeti logist issu sever curtail market opportun
drug diseas therapeut area
pku sever gene therapi candid clinic expect
clinic could limit market opportun
use rct may solv toxic problem associ target
rct manufactur depend continu suppli healthi volunt
unanticip issu futur may limit suppli
cost associ manufactur clinic develop may ultim
compani engin red blood cell player may
ultim prove competit initi believ
current valuat high preclin compani
page
pleas see import disclosur inform page report
exhibit valuat compar compani
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
pku ind file initi data goutfil ind ind ind ind solid tumorfil ind aml post-hsctfil ind targetedfil ind tumorfil ind ind vulgarisfil ind diabetesfil ind shieldingcell-cel interactiontoler induct
found flagship pioneer base discoveri mit
rubiu built proprietari cell therapi platform could potenti
offer transform treatment rare diseas cancer autoimmun
diseas togeth repres market opportun use
red platform rubiu take hematopoiet stem cell healthi volunt
engin off-the-shelf allogen red blood cell express virtual
biotherapeut protein interest within cell cell surfac date
compani gener hundr demonstr versatil platform
engin therapeut cell expect mani properti normal
red blood cell allow compani deliv efficaci safe
conveni therapi broad diseas popul
diseas rct genet engin express potent enzym
within cell treatment patient suffer rare enzym defici
diseas enzym within cell shield
immun system moreov cell expect rel long half-lif
result dose frequenc rang three four month rubiu expect
file ind pku expect initi data
sometim like follow-on indic includ chronic refractori
gout homocystinuria
cancer rubiu engin express hundr thousand copi
one cancer-rel protein cell surfac preclin model
engin cell shown potent cell cell interact abil
induc potent immun respons tumor via activ adapt
innat immun system believ could transform therapi
patient solid hematolog cancer compani expect
initi first clinic studi solid tumor patient relapse/refractori
checkpoint inhibitor lost mhc express
autoimmun diseas rubiu genet engin express well-
character autoimmun disease-caus antigen within cell cell
surfac preclin model cell shown induc immun
toler amelior diseas compani expect select first
clinic candid categori potenti diseas includ pemphigu
vulgari type diabet membran nephropathi
page
pleas see import disclosur inform page report
exhibit rct treat diseas cancer autoimmun diseas
exhibit expect newsflow estim
page
pleas see import disclosur inform page report
timeexpect ind phase i/iia pku data phase i/iia ind solid phase i/ii solid data phase i/ii solid data phase i/iia pivot studi addit ind programrct
rubiu red platform gener red blood cell base biotherapeut
allogen ready-to-us red blood cell ubiquit cell bodi
well character given ubiquit natur cell long histori red
blood cell transfus rubiu believ red blood cell repres ideal cell type
creation versatil safe therapi avoid mani pitfal associ
step gener rct product
obtain hematopoiet stem cell neg healthi volunt
genet modifi cell via lentiviru express biotherapeut protein insid
cell surfac
expand differenti engin progenitor cell enucl
character store dose engin red later use orphan
oncolog autoimmun diseas
figur donor stem cell red cell therapeut
red blood cell hold intrins advantag cellular therapi
predict durat circul red blood cell circul
time day expect similar half-lif
addit expect similar distribut red blood
cell confin bodi vasculatur system
toler presenc certain cellular marker make donor
recipi transfer like success express
safeti rbc expand enucl nucleu mitig
potenti risk cancer
quick develop time underli technolog remain
variou rct rubiu abl go product design
identif month vs year averag develop time
page
pleas see import disclosur inform page report
disadvantag cellular therapi
past attempt modifi rbc cell met sever disadvantag
part also limit applic effort modifi cell nk
cell larg limit use oncolog indic previou issu includ
sever side effect current cellular therapi demonstr robust
efficaci therapi also demonstr seriou side effect
cytokin releas syndrom neurotox fatal addit sinc
current cellular therapi retain edit nucleas chanc
oncogen low still present
therapi differ half-liv
distribut tissu
intens costli manufactur process current cellular therapi
autolog process collect engin cell take week
come signific cost good dose must made individu
patient
stem cell red blood cell
erythropoiesi highly-regul process hematopoiet stem cell bone
marrow differenti erythrocyt due presenc combin growth
factor one epo
earliest recogn erythroid progenitor cell slowli prolifer burst-
form unit-erythroid bfu-e stage erythrocyt take
day includ cell divis
bfu-e cell matur becom rapidli divid colony-form unit-erythroid
cfu-e cell divid time period matur
erythroblast extrud nuclei becom erythrocyt
rbc store
figur erythropoiesi erythrocyt
page
pleas see import disclosur inform page report
rubiu expend signific resourc develop expand rct
manufactur process compani creat patent estat amass
signific amount know-how around manufactur process make
difficult other follow importantli fda review rubiu manufactur
process part pre-ind meet given compani go
ahead rubiu standard rct manufactur process amen
product follow-on product includ
healthi neg blood donor select administ gmcsf
stimul mobil bone marrow cell bone marrow cell
expans blood
hematopoiet stem cell collect purifi donor
isol hematopoiet stem cell expand transduc
lentiviru encod biotherapeut protein
transduc stem cell cultur defin media promot cellular
growth differenti matur enucl red blood cell
express one biotherapeut protein
purifi ensur product includ enucl red
blood cell purifi cell store degre frozen
rubiu sign purchas sale agreement acquisit
foot gmp manufactur facil smithfield rhode island product red
cell deal expect close rubiu plan invest
total year period renov
custom facil includ multipl rct two lentivir vector gmp suit
enabl compani manufactur multipl simultan
pivot clinic studi expect come new facil
page
pleas see import disclosur inform page report
rct diseas better efficaci
safeti
rubiu rare diseas program target enzym defici diseas unmet medic
need compani red platform allow engin human non-human
biotherapeut contain red blood cell
shield immun system
conveni infrequ dose could potenti offer better util
compar nativ pegyl counterpart
importantli rubiu target enzym defici diseas amen
treatment use diseas infus enzym circul
allevi diseas diseas substrat blood vs muscl etc
phenylketonuria pku
treatment classic moder pku could repres
efficaci safer conveni altern treatment pku
compani expect complet ind-en work includ
non-clin pharmacolog toxicolog studi end notabl fda
review manufactur process provid rubiu guidanc
product releas criteria trial design
trial phase i/ii studi expect enrol adult pku
patient skip phase healthi volunt design assess
safeti effect dose dose interv
dose fda provid compani green light start dose
patient activ dose base preclin work
durat enrol anticip could see meaning phe
reduct month
endpoint efficaci measur base reduct phe
approv endpoint addit pk/pd
compani expect releas interim result like posit
data compani expect begin pediatr studi registr phase studi
use adapt design interim data releas specif look
safeti clear dose respons think rubiu show respons rate
time respons rate measur drop phe would competit
base data biomarin palynziq kuvan note togeth product
expect provid peak sale
product candid descript preclin data
rct engin express phenylalanin ammonia-lyas pal base
data gener date compani believ abl reduc
excess phenylalanin pku patient via infrequ low volum iv inject
product compani expect file orphan drug design
page
pleas see import disclosur inform page report
pal natur occur protein found mani speci plant
bacteria yeast fungi found human pal convert free phenylamin
tran -cinnam acid tca ammonia exhibit human tca low
toxic readili convert liver benzoic acid excret
urin importantli unlik normal human protein phenylalanin hydroxylas pah
pal requir cofactor tetrahydrobiopterin sapropterin howev
pal foreign non-human protein administr unprotect pal
lead induct potent immun respons
effici convert phe tca vitro preclin studi rubiu
found pal highli activ measur reduct phe
product tca exhibit importantli result demonstr clear dose-
respons rubiu also note phe uptak limit convers
phe tca import would indic addit transport protein
phe cell need
exhibit vitro dose depend reduct high level phe
concomit gener tca human serum
rct expect approxim circul time
equival normal red blood cell month preclin mous studi
mous express gfp green fluoresc protein pal demonstr
circul time approxim day equival circul time
page
pleas see import disclosur inform page report
normal mous red blood cell exhibit notabl would suggest
could dose infrequ everi month regular circul time human red
exhibit circul time mrct-gfp-pal equival normal mous
cell suggest normal circul time
use preclin data avail clinic data rubiu gener
pharmacodynam model determin start dose
expect reduc phe level target level mol/l
mol/l exhibit rubiu project pal activ
fold higher necessari achiev target clinic respons
exhibit pharmacodynam model inform pal activ target
current pku therapi pitfal
dietari restrict phe-restrict diet goal-standard therapi pku
pku patient diet known lower plasma phe level prevent mental
impair phe-restrict diet entail use medic food exclud item
high phe meat chicken fish dairi product egg nut howev
page
pleas see import disclosur inform page report
diet consid unpalat complianc often low especi
older children adult minor adult patient well control use
diet alon import note phe-restrict diet appear necessari
throughout life prevent neurolog symptom associ elev
biomarin kuvan oral synthet version pah cofactor
approv fda decemb date kuvan gener sale
annual despit use pku popul bmrn estimate kuvan work
increas activ pah requir patient threshold level
function pah present pivot phase studi kuvan pku drug
found safe effect reduc phe level
kuvan two-part pivot studi discuss competit
section drug found elicit respons defin
drop phe test individu eight-day
period less patient week
biomarin palynziq peg-pal approv may fda treatment
adult pku accord biomarin estim palynziq could gener
ww peak sale palynziq pegyl version phenylalanin ammonia lyas pal
palynziq studi two-part pivot clinic program
palynziq pivot studi drug found elicit respons
defin reduct phe blood phe concentr
mol/l patient week
palynziq shown effect reduc phe
number disadvantag could potenti limit commerci uptak
month use greater patient reach us
guidelin goal mol/l
day inject requir complex titrat
treat patient inject site reaction
black warn risk anaphylaxi requir
monitor first dose treat patient hypersensit reaction
patient experienc anaphylaxi episod
induction/titration/mainten dose induct
drug access avail restrict program call palynziq
patient palynziq requir carri epipen time
given drawback current therapi pku patient think
time rubiu show respons rate defin drop
phe coupl safeti think competit
page
pleas see import disclosur inform page report
treatment chronic refractori gout
rubiu plan develop treatment chronic refractori gout
compani estim could run phase i/iia studi patient dose
escal expans pend fda buy aim studi would
determin safeti profil drug correct dose
interv requir achiev uric acid level less mg/dl threshold
diseas symptom allevi uric crystal degrad new crystal
form endpoint basi fda ema approv horizon pharma
product candid descript preclin data
rubiu engin express copi uricas enzym
catalyz convers urat solubl allantoin intracellularli uric acid
transport cell surfac uricas found mammal absent
human rubiu believ abl reduc amount uric
acid blood thu allevi frequenc bone spur gout flare similar
key advantag less anti-drug antibodi inject site reaction less
frequent dose uricas expect shield immun system rct
result safeti concern note pegloticas rtx-
like month less dose frequenc small
limit current therapi
current three class urat low medic gener xanthin oxidas
inhibitor xoi gener brand uricosur drug brand uricas
drug effect remain unmet need
duzallo sale
sale krystexxa
horizon estim peak sale
inhibit
first-lin therapi gener xanthin oxid inhibitor xoi includ
allopurinol febuxostat block uric acid synthesi shown
effect reduc uric acid allopurinol prefer febuzostat due
concern increas cardiovascular risk febuzostat
second-lin therapi patient requir addit control
rel uncommon addit uricosur agent includ
lesinurad/allopurinol probenecid may benefit uricosur agent work
uric acid
reabsorpt kidney ironwood duzallo lesinurad/allopurinol
approv fda treatment patient
achiev target serum uric acid level xoi alon howev
lesinurad increas risk acut kidney injuri fda place black box
warn label gener altern duzallo uptak
limit
third-lin therapi horizon pharma krystexxa pegloticas
pegyl pig uricas administ patient sever gout
refractori treatment treatment highli effect mar
signific disadvantag pegloticas come black box label
page
pleas see import disclosur inform page report
anaphylaxi moreov guidelin indic treatment stop
patient develop hypersensit
gout multicompon diseas metabol inflammatori
compon result metabol genet and/or factor hyperuricemia
result format monosodium urat msu crystal occur crystal promot
acut inflammatori respons mostli self-resolv howev chronic bout
gout lead chronic inflamm promot format tophi crystallin
deposit bone eros site msu crystal deposit usual joint
kidney heart estim million peopl diagnos gout
 gout patient us consid chronic refractori
orphan drug indic rtx-cb treatment
homocystinuria
develop rtx-cb treatment patient symptomat
homocystinuria refractori vitamin compani plan run dose
escal expans studi phase i/iia trial rtx-cb approxim
pediatr patient genet confirm sever hyperhomocysteinemia total
homocystein level um studi design assess safeti proper
dose dose interv rtx-cb achiev maintain goal target level
compani believ phase i/ii registr direct trial approv
primari endpoint reduct total plasma homocystein level
compani note plan seek variou fda design potenti
prioriti review voucher fda
limit current therapi
cardiovascular diseas
cerebrovascular peripher arteri coronari heart diseas venou thromboembol
diseas diseas character sever elev plasma urin
homocystein intermedi amino acid form convers methionin
cystein standard care diet mainli consist fruit veget low-fat
food patient need addit treatment off-label administr folic acid
vitamin shown help approv drug homocystinuria
recordati diseas group rdt cystadan oral betain anhydr solut
approv fda howev cystadan effect everi patient
preclin data would suggest efficaci decreas long-term use
record sale cystadan later sold right drug
product candid descript review preclin data
rtx-cb design express cystathionin -- synthas cb insid rct part
optim compani character transport homocystein serin
rtx-cb secret convers product may ultim determin whether
transport protein also need co-express rtx-cb aim rtx-cb
reduc total plasma homocystein compani also expect administr
infrequ rubiu conduct preclin experi model determin
page
pleas see import disclosur inform page report
requir level cb see clinic activ furthermor level expect
inform clinic dose like administr frequenc pivot trial
homocystinuria result sever clinic manifest includ development
delay ocular abnorm osteoporosi thromboembol diseas atherosclerosi
common genet mutat found patient homocystinuria loss
function mutat regulatori protein respons product express
cb earli life patient homocystinuria fail hit growth mileston
present displac ocular len nearsighted patient
treat progress present sever neurodegener psychiatr disturb
seizur addit patient homocystinuria often sever hypertens
elev risk stroke young age estim
untreat patient stroke event mortal rate
third decad life estim patient diagnos homocystinuria
us eu howev studi suggest preval rate may lot higher
current estim
rubiu engin rct product candid express enzym cytosol
transport cell surfac base preclin work compani believ
design use mostli technolog implement rtx-
treatment sever enzym defici relat diseas
rtx-oxox express oxal oxidas treatment hyperoxaluria
rtx-ald express delta-aminolevulin acid dehydratas treatment
page
pleas see import disclosur inform page report
rct oncolog multipl shot
rubiu rct program oncolog potenti transform therapeut
across wide rang tumor type compani develop suit target
immun cell includ cell nk cell dendrit cell tumor cell initi focu
engin rct express protein
immunostimulatori ligand tumor target bide domain
trigger immun system fight cancer three main program includ
compani first product candid rct design
express togeth activ
adapt innat immun system stimul activ cell
nk cell dendrit cell monocyt neutrophil bind
receptor express cell importantli express
import cell expans differenti inhibit
cell anergi fusion receptor alpha act
stimul effector memori cell nk cell base dual
activ compani believ use treatment
tumor respons well refractori immunotherapi
checkpoint inhibitor compani anticip initi studi focu
patient refractori checkpoint inhibitor across rang variou
solid tumor type patient acut myeloid leukemia aml follow
tumor target rubiu also develop tumor-target
express singl chain fragment bind tumor specif
antigen expect activ t-cell tumor microenviron
monotherapi combo therapi conjunct checkpoint inhibitor
could provid potent select potenti safe treatment hot
activ tumor express specif antigen
rtx-aapc rubiu also develop could potenti function like
antigen present cell apc express tumor antigen fuse major
histocompat complex class mhc cell surfac
compani expect explor use one rtx-aapc patient
solid opportun
design activ adapt innat arm
sustain activ immun system use could lead
robust anti-tumor activ preclin experi
shown activ arm immun system adapt side
cell innat side nk cell express
simul natur immun synaps connect
antigen present cell cell tumor cell nk cell
importantli rubiu believ circul time much
longer antibodi lead continu immun
stimul result better outcom
page
pleas see import disclosur inform page report
sale estim checkpoint
inhibitor estim reach
histor use clinic limit due
dose limit toxic signific bodi preclin data
show potent anti-tumor activ howev
due dose limit toxic bm urelumab death due hepat live
failur drug target limit limit
distribut may liver toxic system toxic
observ target
potent nk cell activ could prevent emerg
resistant/refractori tumor cell mani tumor type loos express
mhc mean evad cell mediat kill howev nk cell recogn
kill cell dont express mhc-i cell surfac rubiu believ
activ adapt cell innat nk cell
immun system could prevent emerg cell resist t-cell kill
use monotherapi combin immunotherapi
addit use treat patient tumor alreadi
progress checkpoint inhibitor
safeti toler rubiu expect distribut similar
normal red blood cell confin vasculatur
spleen liver tumor due limit distribut rubiu believ rtx-
less like on-target tissu effect observ clinic
studi contrast administr immun stimulatori mab protein
lead safeti toler issu
current therapi limit approv checkpoint inhibitor
antibodi work remov immun
suppress adapt
immun system tumor moreov
checkpoint inhibitor shown prolong overal surviv
durabl respons sever phase variou indic howev mani
patient unrespons checkpoint inhibitor addit
mani initi respons mani go progress within matter
month increas effort combin checkpoint inhibitor
immunostimulatori agent
anticip compani begin phase studi follow accept
ind earli estimate interim clinic data potenti
design activ t-cell specif
tumor
tumor microenviron
anti-tumor activ hot cold vascular tumor
expect circul
vasculatur subsequ bind specif tumor antigen expect
activ cell robustli method use monoclon
antibodi pfe utomilumab bm urelumab due part high
express tumor antigen scfv specif locat activ
safeti toler local tumor
express antigen interest reduc likelihood target
importantli tumor-target
demonstr dose limit toxic dlt liver enzym elev observ
mab due lack accumul non-specif tissu
page
pleas see import disclosur inform page report
ultim rubiu believ lead improv outcom
use monotherapi combin checkpoint inhibitor
clinic develop solid tumor
rubiu expect begin phase i/iia studi solid tumor
monotherapi safeti dose find
expans cohort recommend combin dose
safeti dose find combin
expect expans cohort includ patient progress
checkpoint inhibitor lost mhc-i express exampl tumor
includ melanoma non-smal cell lung cancer renal cell carcinoma bladder cancer
head neck cancer rubiu believ success one tumor
type could directli support initi pivot studi potenti develop
earlier line therapi
clinic develop hematolog cancer r/r aml post
addit develop solid tumor rubiu plan conduct phase
ii trial aml patient post allogen hematopoiet stem cell transplant
dose base phase trial solid tumor rubiu believ
studi could primari endpoint relaps free surviv pend fda buy-in
ind applic regulatori path
robust preclin data
shown activ cell potent
antibodi current clinic develop assess cell activ
rubiu use in-vitro human t-cell line assay design measur nf-kb surrog
immun activ nf-kb master regul immun system activ
protein signal initi immun respons assay shown
activ nf-kb higher compar crosslink utomilumab
monoclon antibodi current test sever clinic studi exhibit
notabl increas express protein result dose
depend increas nf-kb activ contrast rct-ctlr control cell
express show background level nf-kb activ
page
pleas see import disclosur inform page report
exhibit activ jurkat t-cell measur nf-kb
rubiu believ robust t-cell prolifer stimul observ
result high express natur
conform rct cell surfac preclin experi
stimul expans cell exhibit activ
measur via product cytokin ifn tnf exhibit compar
utomilumab stimul fold fold increas
t-cell respect exhibit addit administr lead
fold increas ifn tnf product exhibit convers
utomilumab stimul t-cell prolifer minim activ cell
page
pleas see import disclosur inform page report
exhibit vitro prolifer activ primari
cell
maxim stimul prolifer activ
import subpopul cell preclin model use
mous version rubiu observ stimul cell
subpopul cell includ memori cell effector cell
granzym cell exhibit numer studi shown
subpopul cell import durabl respons observ cancer
patient notabl elicit similar level activ prolifer
cell compar anti-mous monoclon antibodi
mab administ dose higher normal data indic mrct-
like stimul maximum activ prolifer cell
page
pleas see import disclosur inform page report
exhibit lead equival level subpopul
activ prolifer dose murin antibodi
importantli result liver toxic remind
clinic studi monoclon antibodi shown liver toxic
mous model liver toxic administr result
increas ast alt exhibit convers administr mab result
signific elev liver enzym
exhibit liver toxic mice compar agonist
express tumor specif scfv bind tumor cell rtx-
epcam rct express tumor antigen epcam scfv effici bound epcam
page
pleas see import disclosur inform page report
express cancer cell line breast cancer colon cancer liver
cancer exhibit control rct express epcam scfv
minim bind cancer cell line compani examin addit rct
express tumor antigen scfv treatment tumor type
exhibit rtx- epcam bind epcam express cancer cell line
preclin data solid tumor
activ cell measur nf-kb product
express induc cell activ similarli
dose-depend manner exhibit similar previou experi crosslink
utomilumab minim activ cell rtc-ctrl cell activ cell
exhibit nf-kb activ jurkat cell
compar activ potent
cell nk cell importantli activ occur without
presenc suggest could overcom tumor evas
preclin experi cell stimul via mab
demonstr greater six-fold increas stimul prolifer
memori cell compar control antibodi compar well utomilumab
recombin combin utomilumab rct-ctrl absenc
cell receptor stimul via mab demonstr expans
memori nk cell nine-fold compar control cell
page
pleas see import disclosur inform page report
observ utomilumab
exhibit potent activ nk cell expans
induc liver toxic mous model mice
administ murin version show increas
ast alt compar administr mrct-ctrl exhibit convers
mice administ mab demonstr signific increas ast moreov liver
infiltr macrophag cell observ mice administ
vs mice administ mab show statist
signific increas cell type liver exhibit
page
pleas see import disclosur inform page report
